NCT05495698

Triple Therapy Convenience by the Use of One or Multiple Inhalers and Digital Support in Chronic Obstructive Pulmonary Disease

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Franciscus Gasthuis · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

TRICOLON is an investigator initiated, prospective, interventional, open-label, randomized, real-world, multi-centre, 3-arms study in the Netherlands. The primary objective is to investigate in COPD patients if single-inhaler triple therapy (SITT) is superior to multi-inhaler triple therapy (MITT) in terms of adherence to inhaled corticosteroids (ICS) therapy and to investigate if SITT with e-health support is superior to MITT and SITT without e-health support.

Conditions

• Copd
• Adherence, Medication

Interventions

Type	Name	Description
DRUG	single-inhaler triple therapy (Trimbow)	Patients in the intervention group will receive the triple therapy in one inhaler in stead of multiple inhalers. The actual medication is the same.
DEVICE	E-health application: Curavista app & FindAir e-device	Patients in intervention group 2 will receive Trimbow and will use the health app of Curavista and the smart-inhaler of FindAir
DRUG	multi-inhaler triple therapy (Qvar + Bevespi)	Patients in the intervention group will receive the triple therapy in multiple inhalers. The actual medication is the same.

Timeline

• Start date: 2022-12-13
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2022-08-10
• Last updated: 2025-08-21

Locations

1 site across 1 country: Netherlands